Skip to main content

Table 1 Baseline Characteristics

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics

Total Population

Age categories

1–6 years

6–12 years

> 12 years

Number of Patients

30

8

14

8

Female/Male

13/17

2/6

6/8

5/3

Age (years)

9.23 ± 3.942

4.54 ± 0.962

9.07 ± 1.619

14.22 ± 2.229

Weight (kg)

30.11 ± 13.161

18.11 ± 4.209

29.10 ± 10.627

43.88 ± 10.346

Weight (SDS)

− 0.15 ± 1.41

0.27 ± 1.35

− 0.06 ± 1.00

− 0.59 ± 0.78

Height (cm)

130.09 ± 18.906

108.19 ± 9.494

130.14 ± 11.374

151.89 ± 7.691

Height (SDS)

−0.04 ± 1.13

0.39 ± 1.56

−0.27 ± 1.39

−0.54 ± 1.15

BMI (kg/m2)

16.99 ± 3.364

15.28 ± 1.274

16.79 ± 3.297

19.04 ± 4.108

BMI (SDS)

0.04 ± 0.97

0.04 ± 0.81

0.10 ± 0.91

−0.43 ± 0.89

HbA1c (%)

9.65 ± 1.998

8.59 ± 0.753

10.32 ± 2.213

9.53 ± 2.159

FPG (mg/dL)

156.93 ± 42.373

136.50 ± 12.862

176.43 ± 49.781

143.25 ± 34.919

Insulin dose (U/kg of body weight/day)

 Basal insulin

0.42 ± 0.134

0.38 ± 0.120

0.46 ± 0.165

0.40 ± 0.069

 Bolus dose

0.49 ± 0.208

0.37 ± 0.115

0.57 ± 0.255

0.48 ± 0.128

  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SDS Standard Deviation Score